dimethyl 4-[2-(4-aminobutoxy)-5-nitrophenyl]-1,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxylate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: dimethyl 4-[2-(4-aminobutoxy)-5-nitrophenyl]-1,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxylate
• 英文别名: dimethyl 4-[2-(4-aminobutoxy)-5-nitrophenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
• 化学式: C₂₁H₂₇N₃O₇
• 分子量: 433.461
• InChiKey: OOZCFDZVXLWKOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  31
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  146
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  dimethyl 4-[2-(4-aminobutoxy)-5-nitrophenyl]-1,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxylate 在 乙酸酐 作用下， 以 二氯甲烷 为溶剂， 生成 dimethyl 4-[2-[4-(acetylamino)butoxy]-5-nitrophenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
  参考文献：
  名称：

  1,4-dihydropyridine derivatives

  摘要：

  一种由一般式（I）表示的1,4-二氢吡啶衍生物：##STR1##其中：R.sup.1和R.sup.2：可以相同也可以不同，每个代表一个可以由氧原子干扰的烷基基团，一个环烷基取代的较低烷基基团或一个卤代取代的较低烷基基团；R.sup.3和R.sup.4：可以相同也可以不同，每个代表一个较低烷基基团；R.sup.5和R.sup.6：可以相同也可以不同，每个代表一个氢原子，一个硝基基团，一个卤原子，一个较低烷基基团，一个较低烷氧基团，一个较低烷硫基团，一个较低烷基磺酰基团或一个较低烷基亚磺基团；R.sup.7：氢原子或一个较低烷基基团；R.sup.8：一个较低烷基基团；一个羟基较低烷基基团，一个芳基烷基基团，一个芳基基团，一个较低酰基基团，一个较低烷基磺酰基团或一个芳氧较低烷基基团，一个芳氧较低烷氧基团，提供R.sup.7和R.sup.8可以结合一个或多个氮原子形成吡咯环，哌啶环，吗啉环或哌啶环或氮杂环，该环可以用一个较低烷基基团或一个芳基烷基基团取代；A：一个烷基基团，一个烯烃基团或一个炔烃基团；以及Y：一个氧原子或一个硫原子；或其盐。

  公开号：

  US04782160A1

文献信息

• Dihydropyridine compounds and pharmaceutical compositions containing them
  申请人：Yamanouchi Pharmaceutical Co., Ltd.

  公开号：US04727082A1

  公开（公告）日：1988-02-23

  A dihydropyridine compound of the following general formula (I) or a salt thereof: ##STR1## wherein R.sup.1 and R.sup.2, which are the same or different, each represents a C.sub.1 to C.sub.10 alkyl group, a lower alkyl group which is interrupted by oxygen atom(s), or a lower alkyl group substituted by C.sub.3 to C.sub.6 alicyclic group(s); R.sup.3 and R.sup.4, which are the same or different, each represents a lower alkyl group; R.sup.5 and R.sup.6, which are the same or different, each represents a hydrogen atom, a nitro group, a halogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkylsulfonyl group, or a lower alkylsulfinyl group; R.sup.7 and R.sup.8, which are the same or different, each represents a hydrogen atom, a halogen atom, a cyano group, a lower alkoxy group, or a lower alkanoylamino group, or R.sup.7 may combine with R.sup.8 to form a naphthyl group together with the adjacent phenyl group; A represents a single bond, a vinylene group (--CH.dbd.CH--), or a ethynylene group (--C.dbd.C--); B represents a single bond or --CH.sub. 2 O--; and m and n, which are the same or different, each represents 0 or an integer of 1 to 5. The compounds are useful for the treatment of various cardiovascular disorders, since they possess both Ca.sup.2+ -antagonistic and adrenergic beta-receptor blocking activities.

  以下一般式（I）的二氢吡啶化合物或其盐：##STR1##其中R.sup.1和R.sup.2，相同或不同，每个代表C.sub.1到C.sub.10烷基，被氧原子中断的较低烷基，或被C.sub.3到C.sub.6脂环烷基取代的较低烷基；R.sup.3和R.sup.4，相同或不同，每个代表较低烷基；R.sup.5和R.sup.6，相同或不同，每个代表氢原子，硝基团，卤素原子，较低烷基，较低烷氧基，较低烷硫基，较低烷基磺酰基或较低烷基亚磺酰基；R.sup.7和R.sup.8，相同或不同，每个代表氢原子，卤素原子，氰基，较低烷氧基或较低烷酰胺基，或R.sup.7可以与R.sup.8结合形成萘基连同相邻苯基；A代表单键，乙烯基（--CH.dbd.CH--）或乙炔基（--C.dbd.C--）；B代表单键或--CH.sub.2O--；m和n，相同或不同，每个代表0或1到5的整数。这些化合物对于治疗各种心血管疾病很有用，因为它们具有Ca.sup.2+ -拮抗和肾上腺素β受体阻滞活性。
• 1,4-Dihydropyridines substituted by 3-aryloxy-2-hydroxypropyl amino
  申请人：Imperial Chemical Industries plc

  公开号：US04873254A1

  公开（公告）日：1989-10-10

  A dihydropyridine of the formula: ##STR1## wherein R.sup.1 and R.sup.2 each is alkyl, alkenyl or alkoxyalkyl, wherein R.sup.3 and R.sup.4 each is alkyl, wherein benzene ring A is unsubstituted or bears one or more additional substituents selected from halogeno, cyano, nitro, trifluoromethyl and alkyl, or bears the substituent .dbd.N--O--N.dbd. attached to the 5- and 6-positions, wherein Ar is as defined in the specification, wherein p is 0 or 1, wherein X is --O-- or --S--, and wherein Y is straight-or branched-chain alkylene or alkenylene each of 2 to 12 carbon atoms which may optionally be interrupted by one or two groups selected from oxygen, sulphur, imino, substituted imino, phenylene, substituted phenylene, pyridylene, cycloalkylene, 1,4-piperazinediyl, 1,4-piperidinediyl and amido groups; or an acid-addition salt thereof, processes for their manufacture and pharmaceutical compositions containing them. The compounds possess either beta-adrenergic blocking or calcium ion slow channel blocking properties, or both such properties, and may be used in the treatment of hypertension.

  一种二氢吡啶的化学式为：其中R.sup.1和R.sup.2各自为烷基、烯基或烷氧基，R.sup.3和R.sup.4各自为烷基，苯环A为未取代或带有一种或多种额外的取代基，包括卤素、氰基、硝基、三氟甲基和烷基，或者带有连接到5-和6-位置的取代基.dbd.N--O--N.dbd.，其中Ar如规范中定义，p为0或1，X为--O--或--S--，Y为直链或支链的2到12个碳原子的烷基或烯基，可能被氧、硫、亚胺、取代亚胺、苯基、取代苯基、吡啶基、环烷基、1,4-哌嗪基、1,4-哌啶基和酰胺基中的一个或两个基团所中断；或其酸盐加合物，其制备方法和含有它们的药物组合物。这些化合物具有β-肾上腺素受体阻滞或钙离子慢通道阻滞性能，或两者的性能，可用于治疗高血压。
• Dihydropyridine compounds, their production, and pharmaceutical compositions containing them
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0167371A2

  公开（公告）日：1986-01-08

  The invention provides a dihydropyridine compound of the following general formular (I) or a salt thereof: wherein R' and R2 are the same or different and selected from C, to C10 alkyl groups, C, to C5 alkyl groups interrupted by oxygen atom(s), and C, to C5 alkyl groups substituted by C3 to C6 alicyclic group(s); R3 and R4 are the same or different C, to C5 alkyl groups; R5 and R6 are the same or different and selected from hydrogen and halogen atoms and nitro, C, to C5 alkyl, C, to C5 alkoxy, C, to C5 alkylthio, C, to C5 alkylsulfonyl and C, to C5 alkylsulfinyl groups; R7 and R8 are the same or different and are selected from hydrogen and halogen atoms and cyano, C, to C5 alkoxy and C, to C5 alkanoylamino groups or combine to form, with the adjacent phenyl group, a naphthyl group; A represents a single bond, or a vinylene (-CH=CH-) or ethynylene group (-C≡C-); B represents a single bond or -CH20-; and m and n are the same or different and selected from 0 and integers of 1 to 5, and methods of making such a compound. The compounds may be used for treatment or prevention of ischemic heart-disease and cardiovascular disorders and may show both Ca2+-antagonistic action and adrenergic betareceptor

  本发明提供了以下通式（I）的二氢吡啶化合物或其盐： 其中R'和R2相同或不同，选自C～C10烷基、被氧原子间断的C～C5烷基和被C3～C6脂环基取代的C～C5烷基；R3 和 R4 是相同或不同的 C 至 C5 烷基；R5 和 R6 是相同或不同的选自氢和卤素原子及硝基、C 至 C5 烷基、C 至 C5 烷氧基、C 至 C5 烷硫基、C 至 C5 烷磺酰基和 C 至 C5 烷基亚磺酰基的基团；R7 和 R8 相同或不同，选自氢和卤素原子、氰基、C, 至 C5 烷氧基和 C, 至 C5 烷酰胺基，或与相邻苯基结合形成萘基；A代表单键，或乙烯基（-CH=CH-）或乙炔基（-C≡C-）；B代表单键或-CH20-；m和n相同或不同，选自0和1至5的整数，以及制造这种化合物的方法。这些化合物可用于治疗或预防缺血性心脏病和心血管疾病，并可同时显示出 Ca2+ 拮抗作用和肾上腺素能 betareceptor
• Dihydropyridine alkanol amines, process for their preparation and pharmaceutical compositions containing them
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0194047A1

  公开（公告）日：1986-09-10

  A dihydropyridine of the formula: wherein R1 and R2 each is alkyl or alkoxyalkyl, wherein R3 and R4, each is alkyl, wherein R5 is alpha-branched-chain alkyl, alkoxyalkyl, arylalkyl or aryloxyalkyl, or acylaminoalkyl, wherein benzene ring A bears one or more substituents selected from halogeno, cyano, nitro, trifluoromethyl and alkyl, or bears the substituent =N-0-N= attached to the 5- and 6-positions; wherein Ar is phenylene, naphthylene, tetrahydronaphthylene, indanylene or pyridylene which is unsubstituted or which bears one or more substituents, wherein p is 0 or 1; wherein X is -0- or -S-; wherein X1 is a direct link or is -0-, -S-, -NH- or -NHS02-; and wherein Y is straight- or branched-chain alkylene which may optionally be interrupted by one or two groups selected from oxygen, sulphur, imino, substituted imino, phenylene, substituted phenylene, pyridylene, cycloalkylene, 1,4-piperazinediyl, 1,4-piperidinediyl and amido groups; or an acid-addition salt thereof, process for their manufacture and pharmaceutical compositions containing them. The compound possess either beta-adrenergic blocking or calcium ion slow channel blocking properties, or both such properties, and may be used in the treatment of hypertension.

  一种二氢吡啶，其式如下 其中R1和R2各自为烷基或烷氧基烷基，其中R3和R4各自为烷基，其中R5为α-支链烷基、烷氧基烷基、芳基烷基或芳氧基烷基或酰氨基烷基，其中苯环A带有一个或多个选自卤代、氰基、硝基、三氟甲基和烷基的取代基，或带有连接到5位和6位的取代基=N-0-N=；其中 Ar 是未被取代的苯基、萘基、四氢萘基、茚基或吡啶基，或带有一个或多个取代基，其中 p 是 0 或 1；其中 X 为-0-或-S-；其中 X1 为直接连接或为-0-、-S-、-NH-或-NHS02-；其中 Y 为直链或支链亚烷基，可任选被一个或两个选自氧、硫、亚氨基、取代亚氨基、亚苯基、取代亚苯基、吡啶基、环烷基、1,4-哌嗪二基、1,4-哌啶二基和氨基的基团打断；或其酸加成盐，以及它们的制造工艺和含有它们的药物组合物。这些化合物具有β-肾上腺素能阻断特性或钙离子慢通道阻断特性，或同时具有这两种特性，可用于治疗高血压。
• 1,4-dihydropyridine derivatives and their production
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0276552A1

  公开（公告）日：1988-08-03

  1,4-dihydropyridine derivatives of formula (I) below, and their salts wherein R¹ and R² are the same or different and selected from alkyl groups which may be interrupted at least once by an oxygen atom, cycloalkyl-substituted C₁-C₆ alkyl groups and halogen-­substituted C₁-C₆ alkyl groups; R³ and R⁴ are the same or different and selected from C₁-C₆ alkyl groups; R⁵ and R⁶ are the same or different and selected from hydrogen and halogen atoms and nitro, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, C₁-C₆ alkylsulfonyl and C₁-C₆ alkylsulfinyl groups; R⁷ is a hydrogen atom or C₁-C₆ alkyl group and R⁸ is a C₁-C₆ alkyl, hydroxy-(C₁-C₆) alkyl, aralkyl, aryl, C₁-C₆ acyl, C₁-C₆ alkylsulfonyl, aryloxy-C₁-C₆ alkyl or aryloxy-­C₁-C₆ alkoxy group or R⁷ and R⁸ form together with the amino nitrogen a pyrrole, piperidine, morpholine, piperazine or azepine ring which may be substituted by C₁-C₆ alkyl or aralkyl; A is an alkylene, alkenylene or alkynylene group; and Y is an oxygen or sulfur atom are medically useful as calcium antagonists of long lasting activity.

  下式(I)的 1,4-二氢吡啶衍生物及其盐类 其中 R¹ 和 R² 相同或不同，选自至少可被氧原子打断一次的烷基、环烷基取代的 C₁-C₆ 烷基和卤素取代的 C₁-C₆ 烷基； R³ 和 R⁴ 相同或不同，选自 C₁-C₆ 烷基； R⁵ 和 R⁶ 相同或不同，选自氢和卤素原子以及硝基、C₁-C₆ 烷基、C₁-C₆ 烷氧基、C₁-C₆ 烷硫基、C₁-C₆ 烷磺酰基和 C₁-C₆ 烷基亚磺酰基； R⁷ 是氢原子或 C₁-C₆ 烷基，以及 R⁸是C₁-C₆烷基、羟基-(C₁-C₆)烷基、芳烷基、芳基、C₁-C₆酰基、C₁-C₆烷基磺酰基、芳氧基-C₁-C₆烷基或芳氧基-C₁-C₆烷氧基或 R⁷ 和 R⁸ 与氨基氮一起形成吡咯、哌啶、吗啉、哌嗪或氮杂环，该环可被 C₁-C₆ 烷基或芳烷基取代； A 是亚烷基、亚烯基或亚炔基；以及 Y 是氧原子或硫原子。